Details for Patent: 9,801,883
✉ Email this page to a colleague
Which drugs does patent 9,801,883 protect, and when does it expire?
Patent 9,801,883 protects IMBRUVICA and is included in three NDAs.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-seven patent family members in eighteen countries.
Summary for Patent: 9,801,883
| Title: | Use of inhibitors of bruton's tyrosine kinase (Btk) |
| Abstract: | Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. |
| Inventor(s): | Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Fernando, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (Incline, CA), Mody; Tarak D. (Sunnyvale, CA) |
| Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
| Application Number: | 15/054,952 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,801,883 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 9,801,883
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | 9,801,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | 9,801,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | 9,801,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION;ORAL | 217003-001 | Aug 24, 2022 | RX | Yes | Yes | 9,801,883 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH 17P DELETION | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-002 | Dec 20, 2017 | RX | Yes | No | 9,801,883*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 9,801,883*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pharmacyclics Llc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-001 | Feb 16, 2018 | RX | Yes | No | 9,801,883*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,801,883
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011261185 | ⤷ Subscribe | |||
| Australia | 2015275321 | ⤷ Subscribe | |||
| Australia | 2018204179 | ⤷ Subscribe | |||
| Australia | 2020202752 | ⤷ Subscribe | |||
| Australia | 2022201741 | ⤷ Subscribe | |||
| Australia | 2022201742 | ⤷ Subscribe | |||
| Australia | 2022201972 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
